# Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

> **NCT06378190** · PHASE1,PHASE2 · RECRUITING · sponsor: **Instituto de Investigación Biomédica de Salamanca** · enrollment: 27 (estimated)

## Conditions studied

- Refractory B-Cell Lymphoma
- B-cell Lymphoma Recurrent

## Interventions

- **BIOLOGICAL:** CAR-T cells therapy

## Key facts

- **NCT ID:** NCT06378190
- **Lead sponsor:** Instituto de Investigación Biomédica de Salamanca
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-11
- **Primary completion:** 2029-07
- **Final completion:** 2030-07
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06378190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06378190, "Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06378190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*